Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently o...

Full description

Bibliographic Details
Main Authors: Pillinger, Genevra, Abdul-Aziz, Amina, Zaitseva, Lyubov, Lawes, Matthew, MacEwan, David J., Bowles, Kristian M., Rushworth, Stuart A.
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544001/

Similar Items

Similar Items